Marketing Communication Content Development
Pubrica develops marketing communication content for pharmaceutical, biotechnology, medical device, diagnostics and healthcare organisations, including website copy, brochures, product descriptions, case studies, campaign material and social copy. Each claim about a medicine or device is governed by the promotional code of every market it reaches, so our scientific marketing writers work to the frameworks that apply: the ABPI Code, EFPIA, the FDA rules enforced by OPDP, PAAB, the Therapeutic Goods Advertising Code and the PMD Act. Every asset is delivered with a substantiation file and names the code under which it was written. COPE and the ICMJE govern journal publication and do not apply to promotional material.
United StatesPermitted, with strict rules
European UnionProhibited · Directive 2001/83/EC
United KingdomProhibited · HMR 2012
AustraliaProhibited · Advertising Code
Canada, Japan and most othersProhibited or tightly restricted
Claim → audience → market → substantiation → accompaniments
- The governing code named first
- Every claim referenced to its source
- Required accompaniments included from the first draft
- Prepared for your internal review process
- Date of preparation and job code
Our Services
Our Eight Marketing Communication Service Areas
Each service area can be commissioned on its own or combined with others.
Who We Serve
Clients We Support with Marketing Communication Content
We support organisations whose review functions require material to be written to the correct promotional code.
Service Limitations
We do not act as your medical, legal and regulatory reviewers, and we do not help you bypass them. That function should remain independent of the people producing material. We deliver material that arrives at review already written to the code, with substantiation attached, so that review is a check rather than a rebuild. We do not write promotion for an unapproved use in any format, because material about unapproved uses is not marketing material. We do not write invented customers, composite patients presented as real, or testimonials attributed to people who did not give them. We do not advise on gifts, hospitality, speaker programmes or other transfers of value; these are matters for your compliance function. We are not a media agency and we do not buy placement. We do not guarantee that material will pass your review, clear a code body or avoid a complaint. Where we consider a claim unsafe, we tell you in writing and then follow your instructions.
Compliance and Standards
Six Promotional Code and Regulatory Frameworks
The market a piece reaches determines which framework governs it. A global asset with localised disclaimers is governed by all applicable codes at once, including the strictest.
The ABPI Code, 2024 edition (United Kingdom)
The current edition, administered by the Prescription Medicines Code of Practice Authority, a division of the ABPI. It sets standards for the promotion of medicines to health professionals and other relevant decision makers, and it applies more widely than many marketing teams expect: material that only mentions a medicine can fall within it. The Human Medicines Regulations 2012 prohibit advertising prescription-only medicines to the general public, and the MHRA publishes its own guidance on advertising and promotion. PMCPA rulings are public, name the company and describe the material.
EFPIA and Directive 2001/83/EC (European Union)
The EFPIA Code of Practice covers the promotion of medicinal products to healthcare professionals and interactions with HCPs, healthcare organisations and patient organisations. National association codes sit beneath it, are often stricter and apply in practice. The statutory basis is Directive 2001/83/EC, which prohibits advertising prescription-only medicines to the general public across the Union. EFPIA’s own page did not state a version date for the consolidated Code when we checked it on 22 September 2026, so we do not quote one and we confirm the applicable version at project start.
FDA and OPDP (United States)
Prescription drug promotion is enforced by the Office of Prescription Drug Promotion under the Federal Food, Drug and Cosmetic Act, principally sections 201, 301 to 304 and 502, with the regulations at 21 CFR parts 200, 201 and 202. Four key dates apply: the clear, conspicuous and neutral final rule for the major statement in DTC television and radio, published 21 November 2023, effective 20 May 2024, compliance date 20 November 2024, at 21 CFR 202.1(e)(1)(ii); final guidance on communications to healthcare providers about scientific information on unapproved uses, 6 January 2025; revised draft guidance on addressing misinformation about medical products, 8 July 2024; and the payor-communications and consistent-with-labeling guidances of 12 June 2018, updated 28 September 2021. OPDP publishes every untitled and warning letter by company and date, so the enforcement record can be checked before writing.
The PhRMA and AdvaMed Codes (US industry conduct)
Voluntary industry codes that function in practice as the operating standard for interactions with US healthcare professionals: the PhRMA Code on Interactions with Health Care Professionals for medicines, and the AdvaMed Code of Ethics for medical technology. They govern speaker programmes, meals, educational items, consulting arrangements and other transfers of value, which are decisions for your compliance function rather than for copywriters. We could not access either body’s own page, so we do not quote a version or an effective date for them here. Where either code governs a specific project, we confirm the current version at that time.
Canada, Australia and Japan (three different structures)
Canada: the PAAB Code of Advertising Acceptance for healthcare-professional material, with Ad Standards handling consumer-directed material, inside Health Canada’s framework under the Food and Drugs Act. Australia: the Therapeutic Goods Advertising Code made under the Therapeutic Goods Act 1989, with Medicines Australia’s Code of Conduct for industry conduct; advertising prescription medicines to the public is prohibited. Japan: the PMD Act (the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices), the name given to the Pharmaceutical Affairs Law in 2014. The MHLW guidelines on sales information provision activities and the JPMA code also apply.
Advertising and endorsement disclosure (on top of everything above)
Where money, product or another material connection links the advertiser to whoever carries the message, such as a sponsored post, a paid byline, an influencer, a patient advocate or a clinician in a campaign, that connection must be disclosed clearly and prominently. In the UK this is governed by the CAP Code enforced by the Advertising Standards Authority, and in the United States by the Federal Trade Commission’s endorsement rules. A platform’s own label or a footer is not sufficient disclosure. Check the medicines code first, because in several markets a testimonial cannot be used at all. We could not access the current FTC text, so we confirm its detail at the time of writing.
Responsible Use of AI
Our Approach to AI Use in Marketing Communication Content
Promotional material is regulated on the substantiation behind each claim. A generated sentence that overstates a benefit is a compliance finding, so we restrict how AI tools are used.
Why We Do Not Publish AI Accuracy Figures
Accuracy figures for AI tools are usually reported by the companies that sell them.
Pubrica therefore does not quote its own accuracy figures, as they would carry the same conflict of interest. Instead, we tell you which tool was used on your project, at which stage, and what a specialist changed afterwards.
Our Process
Our Content Development Process
We test claims against each applicable code before creative work begins, because replacing an unusable campaign line after creative work is complete is costly.
Message, Audience and Market Definition
We confirm the product and its approved labelling, the audience, the markets and the channels. These four factors determine what can be said before writing begins. Promoting a prescription medicine to the public is prohibited in almost every market, a device claim is limited by its intended use, and a payer communication differs from a prescriber communication.
Claim Set Review Against the Applicable Code
We list every claim you want to make, with the evidence that would substantiate it and whether the code permits it in each market. This step takes place before creative and layout work, so that claims that fail are removed at the lowest cost. The output is a short document for your reviewers.
Claim Substantiation
We link each remaining claim to the specific finding that supports it. We report the primary endpoint as the study defined it, absolute alongside relative figures, intervals, and subgroups labelled as subgroups. Where a claim rests on a cross-trial comparison we say so, because this is the most common substantiation failure in this category and the one competitors challenge.
Content Writing with Required Accompaniments
We include prescribing information at the prominence the code requires, the adverse-event statement where it applies, and fair balance throughout the piece. These elements are designed into the first layout, so the asset does not need to be redesigned to fit safety information later. Every asset carries a date of preparation and a job code.
Submission to Medical, Legal and Regulatory Review
Your medical, legal and regulatory reviewers receive the asset and the substantiation file together. The file lists every claim, its reference, the finding relied on and the labelling version checked against, which turns the review meeting into a verification step and shortens the review cycle. We attend the review meeting.
Version Control and Label Change Updates
We record every asset against the labelling version on which it was based. When the label changes, you can identify within an hour which materials need updating.
Request a Free Promotional Claim Assessment
Within two business days and at no cost, we tell you which of your claims the code permits in each market you named, what would substantiate them, what must accompany them and which cannot be used. The assessment is delivered as a short written document.
Previous review comments are the most useful item on this list, because they show what your medical and regulatory reviewers focus on for this product. If a piece has been rejected internally before, please share that document.
Promotional Claim Checker
Check Whether a Promotional Claim Is Permitted
Select what is being promoted, the audience, the market and what the copy does. The checker shows whether the material is permitted for that audience in that market, which framework governs it, what must accompany the claim, and which common problems apply. It covers six areas: unapproved use, comparative claims, quoting a study, testimonials, transfers of value and social channels.
01
Whether it is permitted, what governs it, what must accompany it, and six common problems.
Runs in your browser · nothing sent anywhereThis is a planning aid, not regulatory or legal advice, and it does not replace your medical, legal and regulatory review. That function remains yours. We write material that arrives at your review already written to the code, with the substantiation referenced and the accompaniments in place, so that review is a check rather than a rebuild. Publication ethics standards: COPE and the ICMJE govern journal publication, including authorship, editorial decisions, corrections and retractions. They do not apply to promotional material; the frameworks above do.
Sources and items we could not confirm. United Kingdom: the current edition of the ABPI Code is the 2024 edition, administered by the PMCPA — confirmed on the PMCPA’s own site on 22 September 2026. Europe: EFPIA Code scope confirmed on efpia.eu the same day; the page we read does not state a version date for the consolidated Code, so we quote none. United States: OPDP’s statutory and regulatory basis, and the dates of the payor, consistent-with-labeling, unsolicited-requests, SIUU and misinformation guidances, from the FDA’s own OPDP regulatory information page; the clear, conspicuous and neutral final rule from the Federal Register of 21 November 2023. OPDP publishes every untitled and warning letter it issues, by company and date, so the enforcement record for any claim type can be checked before writing. Items we could not confirm: the current version and effective date of the PhRMA Code and the AdvaMed Code, the current edition of the PAAB Code, the current Australian advertising Code instrument, and the current text of the FTC endorsement rules, as these sources could not be accessed. Where any of them governs a specific piece, we confirm the version at the time of writing.
Our Experts
Your Marketing Communication Team
A named team of subject specialists stays with your project from scoping to delivery. Your project coordinator introduces each team member by name before work begins.
Reviews the scientific content for accuracy and confirms that each conclusion is supported by the evidence. Each expert is matched to your field.
Writes the content against the brief and the applicable code of practice, with every claim traceable to its reference.
Reviews the content for scientific accuracy, fair balance and compliance with the applicable code before it reaches your internal review.
Manages the timeline, keeps you informed at each stage and coordinates the team so that questions are answered and deadlines are met.
Sample Work
Sample Claim and Substantiation File
An asset moves through medical, legal and regulatory review more efficiently when each claim arrives with its supporting finding, is stated no more broadly than that finding supports, and has the required accompaniments in place. Use the tabs to view each part, then open the full file.
Claim and substantiation file
Prescription medicine · HCP material · 3 markets
Claims · evidence · markets · accompaniments
17 claims in, 15 out2 removed, 4 narrowed
- Claims logged
- 17, each with the reference, the specific finding relied on, the population it applies to and the labelling version checked against.
- Rested on a cross-trial comparison
- 2. Neither was retained. Comparisons across trials with different populations, endpoints and eras do not hold up when a competitor challenges them.
- Wider than the evidence
- 4. Each was true only for a narrower population, dose or duration than the copy claimed, and was restated to match the finding.
- Referenced to a press release
- 1. Traced to the underlying publication, where the finding was smaller and the interval was not informative. Removed.
- Intervals added
- 6. The draft used point estimates only. Intervals now appear wherever an estimate does, as clinical audiences expect.
- References opened and read
- 14. Two did not support the sentences attached to them, as both had been carried over from a previous campaign.
- Markets
- Three. One asset was briefed and three were delivered, because the codes differ enough that a shared asset with localised disclaimers would have been non-compliant in two markets.
- United Kingdom
- ABPI Code, 2024 edition, administered by the PMCPA. Prescribing information and the adverse-event reporting statement required at the prominence the Code sets. Two claims removed that were acceptable elsewhere.
- European Union
- EFPIA and the relevant national association code, over Directive 2001/83/EC. The national code was stricter than EFPIA on one point, which is common and is the reason “EU-compliant” is not a meaningful status.
- United States
- FDA rules enforced by OPDP, with the PhRMA Code for conduct. Fair balance carried through the piece rather than concentrated at the end, and the brief summary handled in the print format.
- Public reach
- The material is for healthcare professionals. Two channels in the plan were open to the public, which in the UK and EU makes a prescription-medicine claim a problem regardless of who it was intended for. Those channels now carry non-product material.
- What a single global asset would have cost
- Withdrawal in two markets. The three-asset approach had a higher quote but cost less by the second review cycle.
3 accompaniment failuresAll three issues resolved before review
Redacted extract · product, indication, client and every figure changedSubstantiation file, as delivered
One content set, three markets, seventeen claims. Use the tabs to see each part.
The claims tab shows the most significant finding. The approved campaign line asserted superiority on the basis of a non-inferiority trial. The study design does not support that claim, regardless of wording, and a competitor could challenge it in a complaint.
The markets tab shows the largest cost difference. One asset was briefed and three were delivered, because a shared asset with localised disclaimers would have been non-compliant in two markets. The approach had a higher quote but cost less by the second review cycle.
On request, we provide a sample substantiation file for a content set similar to yours, with the same product type, audience and markets.
Marketing communication · sample substantiation file
Claim and substantiation file — prescription medicine, HCP material, three markets
A real file with the product, indication, client and every figure changed. The structure, categories of finding and documentation format are as delivered. On request, we can prepare one for a content set like yours.
1What this document is for
Your medical, legal and regulatory reviewers read this document alongside the asset. It records every claim, its reference, the specific finding relied on, the population it applies to and the labelling version checked against. It is produced during writing rather than assembled for the review meeting.
| Element | How it was handled |
|---|---|
| Scope | A content set for healthcare professionals: a sales aid, a product page, a conference panel and supporting digital copy. |
| Markets | United Kingdom, one EU member state, United States. Briefed as one asset; delivered as three. |
| Claims | 17 logged, each traced to the finding that supports it. |
| Evidence | 14 references opened and read against the statements attached to them. |
| Labelling | Every claim checked against the current prescribing information in each market, with the version recorded per asset. |
| Reviewer | A writer in the therapy area, plus a second reader who did not write the copy. |
This file is not regulatory or legal advice and does not replace your own review. It is designed to make that review faster.
2The seventeen claims
| As drafted | Outcome | Why |
|---|---|---|
| “Better outcomes than the standard of care.” | Removed and rewritten | The supporting trial was a non-inferiority study, which does not support a superiority claim in any of these markets. The claim was replaced with one the design supports. This is the most common substantiation failure in the category and the one a competitor’s medical team is most likely to challenge. |
| “A 38% reduction.” | Narrowed | A relative figure on an absolute difference of 2.1 percentage points. Both now appear together, as clinicians usually ask for the absolute figure. |
| A secondary endpoint used as the headline | Reordered | Real, prespecified and secondary, in a trial whose primary endpoint showed a smaller effect. Now reported after the primary and labelled as secondary, where a reviewer would expect it. |
| Two claims resting on a cross-trial comparison | Removed | Different populations, endpoints and eras. Cross-trial comparisons do not hold up when challenged. |
| One claim referenced to a press release | Removed | Traced to the underlying publication, where the finding was smaller and the interval was not informative. A press release is not a valid reference. |
| Four claims wider than their evidence | Narrowed | Each was true only for a narrower population, dose or duration than the copy stated, and was restated to match the finding. |
| Eleven claims | Unchanged | Supported as written by the evidence cited. The file records which claims are acceptable, because a document listing only problems lengthens a review. |
3How the three markets differed
| Market | What governs | What changed |
|---|---|---|
| United Kingdom | The ABPI Code, 2024 edition, administered by the PMCPA, over the Human Medicines Regulations 2012, with MHRA guidance alongside. | Prescribing information and the adverse-event reporting statement required at the prominence the Code sets. Two claims acceptable elsewhere were removed. The Code also applies to material that only mentions a medicine, which is wider than many marketing teams assume. |
| European Union | The EFPIA Code and the relevant national association code, over Directive 2001/83/EC. | The national code was stricter than EFPIA on one point. This is common, and it is why “EU-compliant” is not a meaningful status for an asset: compliance is assessed per member state. |
| United States | FDA rules enforced by OPDP under the FD&C Act, with the regulations at 21 CFR parts 200, 201 and 202; the PhRMA Code for conduct. | Fair balance carried through the piece rather than concentrated at the end, and the brief summary handled in the print format. OPDP publishes every untitled and warning letter it issues, so the enforcement record on this claim type was read before writing. |
| Public-facing channels | Prohibition on promoting prescription medicines to the general public. | The material is for healthcare professionals, but two channels in the media plan were open to the public. In the UK and EU, this makes a prescription-medicine claim a problem regardless of the intended audience, because reach is the test. Those channels now carry non-product material. |
| One asset or three | — | Three. A shared asset with localised disclaimers would have been non-compliant in two markets. The approach had a higher quote but cost less by the second review cycle. |
4Required accompaniments
| Finding | Resolution |
|---|---|
| Prescribing information was going to be fitted in after layout | Accompaniments cannot be fitted in after layout. The piece was redesigned so that they are part of the layout, which avoided a second design pass. |
| Risk information concentrated in a block at the end | Fair balance requires benefit and risk to be presented with comparable prominence throughout, rather than safety text at the bottom of a page. The piece was rebalanced throughout. |
| No adverse-event reporting statement in the UK and EU versions | Required in both versions and omitted in both. Added in the form and prominence each code specifies. Omissions of this kind are usually found by a code body rather than a reviewer. |
| Date of preparation and job code | On every asset, with the labelling version recorded against each, so that materials affected by a label change can be identified within an hour. |
| Digital formats | Two planned formats could not carry the required prescribing information. The claim was removed from those formats rather than shortening the safety information, because a character limit does not justify omitting it. |
| Social moderation | A short policy written alongside the copy, because a company account that likes, shares or replies to a post can adopt a third party’s claim as its own. It is a compliance document. |
5What was handed over
| Artefact | Why it matters afterwards |
|---|---|
| Three market versions of the content set | Written to each code rather than localised from one. |
| The claim and substantiation file | Every claim, reference, finding, population and labelling version. It is what your reviewers read alongside the asset, and what answers a code complaint in hours rather than weeks. |
| The rejected-claims list | Each claim removed, with the reason, so that the same claim does not reappear in the next campaign. |
| The labelling version register | Which asset was built on which version of the prescribing information, in each market. |
| The social moderation policy | A short policy setting out how the company account handles third-party content. |
| A note on what we did not do | We did not advise on any transfer of value, review the material for legal risk or approve it. Those are your functions, and the note states this in writing. |
Limitations: we do not claim that this material will pass your review, clear a code body or avoid a complaint, as no supplier controls those outcomes. A substantiation file allows your reviewers to focus on judgement rather than locating references, allows a challenge to be answered from a document, and shows which assets to withdraw when the label changes.
Benefits
Benefits and Limitations of Early Claim Review
No supplier can promise that material will pass your review or avoid a complaint. Checking claims first reduces the number of review cycles and identifies problems before creative work rather than after it.
Packages
Four Marketing Communication Content Packages
Deliverables are specified as countable pages, posts and pieces, with turnarounds and prices shown for each package. The substantiation file is also available on its own and can be applied to copy written by any team.
Substantiation for copy you already have
For material written in-house or by an agency before it enters review, to confirm that it was written to the correct code
From $1,200up to 20 claims · 1 market · no copywriting
Delivery 5 business days
- ✓Every claim traced to the finding that supports it
- ✓References read in full and checked against each claim
- ✓Claims broader than their evidence narrowed, with suggested wording
- ✓Accompaniments checked against the governing code
- ✓The labelling version recorded against each claim
Credited in full against a content set commissioned within 60 days.
View a sample Select File onlyA core content set
For a launch, a refresh, or a first fully documented set of material
From $1,9005 web pages · 1 brochure · 10 social posts · 1 market
Delivery 7–10 business days
- ✓Company profile or brochure, and product or service descriptions
- ✓Website copy to five pages, written to the approved labelling
- ✓Social copy to ten posts, with the moderation policy
- ✓The claim set tested against the code before drafting
- ✓The substantiation file, included
Each additional market is a separate deliverable, not a localisation pass.
View a sample Select StandardA programme across formats
For ongoing marketing across more than one format, working within your review process
From $4,80010 web pages · 1–2 white papers · 4 blogs · 20 posts · 2 newsletters
Delivery 12–15 business days
- ✓Everything in Standard, at programme scale
- ✓White papers or case studies, with consent handled where patients appear
- ✓A claim library your other agencies can work from
- ✓Written to your templates, your review workflow and your job-code system
- ✓We attend your review rather than handing over a draft
Many clients choose this package, because a claim library reduces work on every subsequent asset.
View a sample Select ProfessionalA full programme, multi-market
For launches and portfolios across markets with different codes, scheduled around the review cycle
From $11,50020 web pages · 2–3 long-form · 6–8 blogs · 30 posts · press and email
Delivery 20–25 business days
- ✓Everything in Professional, across formats and markets
- ✓Press releases written to report a clinical result accurately
- ✓Email campaigns, with the accompaniments each format can carry
- ✓Market versions written to each code, not localised from one
- ✓A labelling version register across the whole estate
Multilingual work is quoted separately and includes translation and re-checking against each market’s code.
View a sample Select PremiumDeliverables
The substantiation file
Every claimwith its finding
And the population it applies to
More than a reference list: the specific finding each claim rests on, the population it applies to and the labelling version checked against. Your reviewers read it alongside the asset, and it allows a code complaint to be answered in hours.
Deliverables
The rejected-claims list
Removed claimswith reasons
The rejected-claims list
Each claim that was removed, with the reason, so that the same line does not reappear in a later campaign.
Deliverables
The version register
Each assetagainst its labelling
With date of preparation and job code
Which asset was built on which version of the prescribing information, in which market. When a label changes, it allows the affected materials to be identified in an hour rather than over a fortnight.
Available with any package: independent review of material written elsewhere before it reaches your reviewers; a claim library built once for use by all your agencies; multilingual versions, including re-checking against each market’s code; conference and congress material; patient-facing material where permitted, written to a target reading level; an audit of existing content against a changed label; and expedited delivery where capacity allows.
Quality Assurance
Our Service Commitments and Limitations
We set out our commitments and the limits of our service clearly, because no supplier can promise review or code outcomes.
Our revision commitment
Revision Support Until Agreed Requirements Are Met
Within the agreed scope, we revise the material until it meets the brief and the code to which it is written, with no limit on rounds, and the writer remains available throughout your review cycle.
01
Every claim arrives with its evidence
Each claim is delivered with the specific finding, population, reference and labelling version. Any claim we cannot substantiate is excluded from the copy, and we tell you which claims those were.
02
The code is confirmed before drafting
We confirm the current version for each market at the start of each project. Where we cannot verify a version, we tell you.
03
Concerns raised in writing
Where we consider a claim unsafe, we tell you in writing before proceeding. We then follow your instructions, and the record shows our advice.
04
Corrections at our cost
Within the agreed scope, if a claim is incorrectly substantiated, an accompaniment is missed or a code version is wrong because of our error, we correct it at no cost and inform you first.
Service Limitations We do not guarantee that material will pass your review, clear a code body or avoid a complaint. No supplier can make these promises. We are not your medical, legal and regulatory reviewers and we do not help you bypass them. We do not write promotion for an unapproved use in any format, because material about unapproved uses is not marketing material. We do not write invented customers, composite patients presented as real, or testimonials attributed to people who did not give them. We do not advise on gifts, hospitality, speaker programmes or other transfers of value; these are matters for your compliance function. We are not a media agency and we neither buy nor arrange placement, although we write the disclosure that a paid placement requires. We do not cite publication-ethics bodies as the compliance framework for promotional material, because they do not govern it.
Free claim check
Send us the claims you want to make, in draft form, with the markets and audiences you have in mind. Within two business days and at no cost, we tell you which claims each code permits, what would substantiate them, what must accompany them and which cannot be used. Identifying an unusable claim at this stage costs far less than after creative work or publication.
Independent review of existing copy
Send us material written by an agency or in-house team, and we will review it against the governing code and the labelling it describes before it reaches your reviewers. Common findings include a relative figure without its absolute, a secondary endpoint used as a headline, a cross-trial comparison, a missing accompaniment and a claim written to the wrong market’s rules. The first ten claims are reviewed at no cost.
Working Within Your Existing Process
We work with your templates, claim library, job-code system, review workflow and document management, so material arrives in the format your validated process requires. Where you have no process, we will propose and document one. We attend the review meeting rather than only handing over a draft.
Confidentiality and Conflicts of Interest
We sign a non-disclosure agreement before any material is shared. Unpublished data, launch plans, labelling drafts and review correspondence are held under the UK GDPR on access-controlled systems within a quality management system certified to ISO 9001:2015 (certificate H3CR9TCU20251212INDQM10N), kept only as long as the project requires and never used for training. We do not work on competing products in the same indication at the same time, and we tell you about any potential conflict before accepting the work.
Client Stories
Client Feedback on Marketing Communication Projects
Testimonials are rephrased from client feedback and do not claim any review outcome or campaign result.
“Our campaign line claimed superiority off a non-inferiority trial. They said so before the creative was built, not after.”
“Our reviewers got the substantiation file with the asset. It went through in one pass for the first time.”
“Two channels in our media plan were open to the public. Nobody had noticed what that meant for a prescription product.”
FAQs
Marketing Communication Content FAQs
If you are unsure whether a claim can be used, send it with the markets and audiences, and we will reply within two business days. Ask an expert. No quote is required.
We develop website and product copy, company profiles and brochures, sales aids and detail material, case studies and customer stories, campaign and launch material, social and digital copy with its moderation policy, press releases and media material, email campaigns, and congress and conference material. We also provide two services that are not copywriting: the substantiation file that documents every claim against its supporting finding, and independent review of material written by an agency or in-house team before it reaches your reviewers. We work with pharmaceutical, biotechnology, medical device, diagnostics and health service organisations, and with the corporate and B2B organisations that sell to them.
Because they do not govern promotional material. COPE and the ICMJE govern journal publication: authorship of research papers, editorial decisions, corrections, retractions and publication ethics. Website copy, brochures, sales aids and campaigns are governed instead by the promotional code of every market the material reaches: the ABPI Code in the UK, EFPIA and national codes in the EU, FDA rules enforced by OPDP and the PhRMA and AdvaMed Codes in the US, PAAB in Canada, the Therapeutic Goods Advertising Code in Australia and the PMD Act in Japan.
In almost no market. The European Union prohibits advertising prescription-only medicines to the general public under Directive 2001/83/EC; the United Kingdom prohibits it under the Human Medicines Regulations 2012; Australia prohibits it under its Therapeutic Goods Advertising Code. The United States is one of very few countries that permit it, and New Zealand is the other example usually cited. Where it is permitted, strict rules apply: the FDA’s final rule requiring the major statement in DTC television and radio advertisements to be presented in a clear, conspicuous and neutral manner was published on 21 November 2023, took effect on 20 May 2024 and had a compliance date of 20 November 2024. Elsewhere, disease-awareness material that does not identify the product may be possible, but the boundary is difficult to maintain, because a campaign that names no medicine but is recognisably about one is precisely what regulators examine. If you take that route, we check the code before creative work begins.
Only if you have a study that shows it. Comparative claims are permitted in most markets and are the claims most often challenged, usually by the named competitor. Three conditions apply: the comparison must be fair and like for like on a clinically meaningful measure rather than a favourable subgroup; it must be substantiated by suitable data, which in medicines advertising generally means a head-to-head trial rather than a cross-trial comparison; and it must remain true, because a comparison that was accurate when written can later become a compliance problem. The most common failure is a superiority claim based on a non-inferiority trial. A non-inferiority result does not support a superiority claim in any of these markets, regardless of wording, and a competitor may challenge it in a complaint.
No. The same rules apply to social media, and assuming otherwise is a common mistake. This has three consequences. Character limits do not remove requirements: if a claim requires prescribing information or a safety statement, the claim should not be used in a format that cannot carry it. Reach determines the audience: material aimed at healthcare professionals on an open channel is available to the public, which is a problem in markets that prohibit public promotion of prescription medicines. Finally, interactions count as content: a company account that likes, shares or replies to a post can adopt a third party’s claim as its own, which is why the moderation policy is a compliance document. On correcting misinformation about your own products online, the FDA issued revised draft guidance on 8 July 2024, replacing its 2014 draft.
We use your style guide, claim library and terminology, together with two or three previous pieces you were satisfied with, which often show the intended voice more clearly than a guide. Where several style guides conflict, we will point this out. In regulated material, much of the content is determined by the code and the labelling, so brand voice has less room than in other material, and we write it within the space that remains.
Yes, and it involves more than translation. A translated asset must be re-checked against the code of the target market, because codes differ on what may be claimed, what must accompany it and whether the audience may be addressed at all. A national association code in the EU is often stricter than EFPIA, which is why “EU-compliant” is not a meaningful status for an asset. Approved labelling also differs by market, so a claim that matches the label in one country may not match it in another. Localising the disclaimers on a single global asset is a common way for a piece that is compliant in one market to become non-compliant in another. We quote market versions as separate deliverables from a shared evidence base. This has a higher initial quote but usually costs less by the second review cycle.
We write for your review, attend it, and do not try to shorten it by other means. Material arrives with the substantiation file attached, listing every claim, its reference, the specific finding relied on, the population and the labelling version, which turns the review meeting into a verification step and reduces review cycles. We work to your templates, job-code system and document management rather than introducing a second process. We do not help you bypass that function. It should remain independent of the people producing the material. Where your reviewers disagree with us, their decision applies; where we consider a claim unsafe, we tell you in writing first.
Yes. A complete sample is available on this page: a claim and substantiation file for a prescription-medicine content set across three markets, with the product, indication, client and every figure changed. It includes a campaign line withdrawn because a non-inferiority trial cannot support a superiority claim, two claims removed for relying on cross-trial comparison, and a recommendation to produce three market versions where one had been budgeted. On request, we can prepare a sample for a content set similar to yours. Client work is confidential, so all samples are redacted or composite. A sample shows our method, and the free claim check shows how we would handle your product.
Related Services
Related Services for Marketing Communication
Services that provide the evidence behind claims, the regulatory frameworks, and non-promotional content.
1EVIDENCE AND LITERATUREdata and synthesis
Clinical literature reviewAppraisal of the evidence behind a claim. Biostatistics and programmingStatistical analysis behind the figures in a claim.2SCIENTIFIC COMMUNICATIONparent and related services
Scientific medical communicationThe parent page, covering the regulatory landscape for every market. Thought leadership and editorial designNon-promotional content, governed by different rules.3NON-PROMOTIONAL CONTENTeducation and labelling
CME content developmentAccredited education with independent content control. Regulatory writingLabelling, SmPCs and the documents the claims have to agree with.Insights
Further Reading on Promotional Rules and Evidence Publication
Three articles on the rules that determine where evidence about a product can be published.
Request a Free Promotional Claim Assessment
Within two business days and at no cost, we tell you which claims the code permits in each market you named, what would substantiate them, what must accompany them and which cannot be used. Identifying unusable claims at this stage avoids rework later.